Patents by Inventor Eric Voight
Eric Voight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220251123Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.Type: ApplicationFiled: September 2, 2021Publication date: August 11, 2022Inventors: Kathleen Ann Martin, Carmela Sidrauski, Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
-
Patent number: 11149043Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.Type: GrantFiled: April 9, 2021Date of Patent: October 19, 2021Assignees: Calico Life Sciences LLC, AbbVie Inc.Inventors: Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
-
Publication number: 20210300863Abstract: A method of preparing a compound of Formula (I) comprising reacting the compound of Formula (A) with a base and a compound of Formula (B) to yield a compound of Formula (C).Type: ApplicationFiled: August 1, 2019Publication date: September 30, 2021Applicant: Intervet Inc.Inventors: Eric Voight, Christophe Pierre Alain Chassaing, Hans Peter Niedermann, Stephan Veit, Claudia Scheipers
-
Publication number: 20210230195Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.Type: ApplicationFiled: April 9, 2021Publication date: July 29, 2021Inventors: Kathleen Ann Martin, Carmela Sidrauski, Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
-
Publication number: 20190358214Abstract: The present invention features compositions and methods for the treatment of HCV infection. In one embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) Compound 2a or a pharmaceutically acceptable salt thereof. In another embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) a prodrug of Compound 2a (e.g., one of Compounds 2b-2k or Examples 3-1 to 3-10) or a pharmaceutically acceptable salt of said prodrug.Type: ApplicationFiled: November 13, 2017Publication date: November 28, 2019Applicant: AbbVie Inc.Inventors: Brian Brown, Hui-Ju Chen, David DeGoey, Geoff Halvorsen, John Hartung, Howard R. Heyman, Nathan Ide, Dale Kempf, Allen C. Krueger, Tao Li, Tongmei Li, Steven R. Martinez, Christopher C. Marvin, John T. Randolph, Eric Voight, Rolf Wagner, Jaclyn Chau
-
Publication number: 20190224220Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.Type: ApplicationFiled: April 20, 2017Publication date: July 25, 2019Applicant: AbbVie Inc.Inventors: Philip R. Kym, Eric Voight
-
Publication number: 20190135827Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: January 8, 2019Publication date: May 9, 2019Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Rameshchandra Krishna Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
-
Publication number: 20190127356Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: December 19, 2018Publication date: May 2, 2019Inventors: Robert J. Altenbach, Andrew Bogdan, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
-
Patent number: 10053474Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: GrantFiled: May 5, 2017Date of Patent: August 21, 2018Assignee: AbbVie Inc.Inventors: Jaclyn Chau, Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight, Brian S. Brown, Steven R. Martinez, Anurupa Shrestha, Howard R. Heyman
-
Publication number: 20180037587Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: October 17, 2017Publication date: February 8, 2018Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Rameshchandra Krishna Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xeuqing Wang, Ming C. Yeung
-
Publication number: 20180022763Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: ApplicationFiled: May 5, 2017Publication date: January 25, 2018Applicant: AbbVie Inc.Inventors: Jaclyn Chau, Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight, Brian S. Brown, Steven R. Martinez, Anurupa Shrestha, Howard R. Heyman
-
Patent number: 9840513Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: July 8, 2016Date of Patent: December 12, 2017Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Ramesh Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xeuquing Wang, Ming C. Yeung
-
Publication number: 20170190693Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: March 23, 2017Publication date: July 6, 2017Inventors: Robert J. Altenbach, Andrew Bogdan, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
-
Patent number: 9676797Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: GrantFiled: September 1, 2016Date of Patent: June 13, 2017Assignee: AbbVie Inc.Inventors: Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Jaclyn Chau, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight
-
Patent number: 9642831Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: October 28, 2015Date of Patent: May 9, 2017Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Robert J. Altenbach, Andrew Bogdan, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
-
Publication number: 20170057981Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: ApplicationFiled: September 1, 2016Publication date: March 2, 2017Applicant: AbbVie Inc.Inventors: Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Jaclyn Chau, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight
-
Publication number: 20170015675Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: July 8, 2016Publication date: January 19, 2017Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Ramesh Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xeuqing Wang, Ming C. Yeung
-
Publication number: 20160120841Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: October 28, 2015Publication date: May 5, 2016Inventors: Philip R. Kym, Xueqing Wang, Xenia B. Searle, Bo Liu, Ming C. Yeung, Robert J. Altenbach, Eric Voight, Andrew Bogdan, John R. Koenig
-
Patent number: 7998993Abstract: Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.Type: GrantFiled: October 23, 2008Date of Patent: August 16, 2011Assignee: Abbott LaboratoriesInventors: Richard J. Perner, John R. Koenig, Stanley DiDomenico, Jr., Erol K. Bayburt, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Anil Vasudevan, Eric Voight
-
Publication number: 20090124666Abstract: Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.Type: ApplicationFiled: October 23, 2008Publication date: May 14, 2009Applicant: ABBOTT LABORATORIESInventors: Richard J. Perner, John R. Koenig, Stanley Didomenico, JR., Erol K. Bayburt, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Anil Vasudevan, Eric Voight